Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (461-470 of 497) with videos related to

Pageof 50
Sort By:
Thrombosis Journal|January 2, 2019
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III studyAnthonie W A Lensing, Christoph Male, Guy Young, et al.
Journal of the American College of Cardiology|July 2, 2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery DiseaseJohn W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
The Lancet. Neurology|October 3, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trialScott E Kasner, Balakumar Swaminathan, Pablo Lavados, et al.
Stroke|September 20, 2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS TrialMukul Sharma, Eric E Smith, Lesly A Pearce, et al.
Circulation|January 23, 2019
Stroke Outcomes in the COMPASS TrialMukul Sharma, Robert G Hart, Stuart J Connolly, et al.
JAMA Neurology|October 19, 2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical TrialAshkan Shoamanesh, Robert G Hart, Stuart J Connolly, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Circulation|October 12, 2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PADConnie N Hess, E Sebastian Debus, Mark R Nehler, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
Pageof 50

Showing results (461-470 of 497) with videos related to

Sort By:
Pageof 50
Thrombosis Journal|January 2, 2019
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III studyAnthonie W A Lensing, Christoph Male, Guy Young, et al.
Journal of the American College of Cardiology|July 2, 2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery DiseaseJohn W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
The Lancet. Neurology|October 3, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trialScott E Kasner, Balakumar Swaminathan, Pablo Lavados, et al.
Stroke|September 20, 2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS TrialMukul Sharma, Eric E Smith, Lesly A Pearce, et al.
Circulation|January 23, 2019
Stroke Outcomes in the COMPASS TrialMukul Sharma, Robert G Hart, Stuart J Connolly, et al.
JAMA Neurology|October 19, 2020
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical TrialAshkan Shoamanesh, Robert G Hart, Stuart J Connolly, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Circulation|October 12, 2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PADConnie N Hess, E Sebastian Debus, Mark R Nehler, et al.
Journal of the American College of Cardiology|October 29, 2021
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PADConnie N Hess, Manesh R Patel, Rupert M Bauersachs, et al.
Pageof 50